Welcome, New MassBio Members

Mar 01, 2017



ABL is a biologics CRO and CMO with over 50 years of experience partnering with clients to meet their preclinical and clinical product development goals. Our expertise with vaccines and therapeutics includes in vivo and in vitro immunomonitoring and challenge testing, along with cGMP manufacturing utilizing mammalian, microbial and virus systems. Services include GCLP immunomodulation for PhI/PhII clinical trials.

American Heart Association

The American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, our organization now includes more than 22.5 million volunteers and supporters. We fund innovative research, fight for stronger public health policies, and provide critical tools and information to save and improve lives. Our nationwide organization includes 156 local offices and more than 3,000 employees. We moved our national headquarters from New York to Dallas in 1975 to be more centrally located. The American Stroke Association was created as a division in 1997 to bring together the organization’s stroke-related activities. What We Do: To improve the lives of all Americans, we provide public health education in a variety of ways. We’re the nation’s leader in CPR education training. We help people understand the importance of healthy lifestyle choices. We provide science-based treatment guidelines to healthcare professionals to help them provide quality care to their patients. We educate lawmakers, policymakers and the public as we advocate for changes to protect and improve the health of our communities.

Pepper Hamilton

Pepper Hamilton LLP is a multi-practice law firm with more than 500 lawyers nationally. The firm provides corporate, litigation and regulatory legal services to leading businesses, governmental entities, nonprofit organizations and individuals throughout the nation and the world. We take a proactive approach to our representation of life sciences companies by organizing around client objectives and bringing together lawyers with a variety of skills and experience into a formal, interdisciplinary life sciences practice. This holistic approach enables us to provide comprehensive counseling to life sciences companies at every stage of their development as a company and every stage of the product life cycle, including discovery, development, manufacturing, marketing and sales. Our clients must navigate this pathway in a heavily regulated and constantly changing environment, which includes escalating business, financing and pricing pressures as well as the constant threat of government investigations, and commercial, patent and mass tort products liability litigation. Through our experience, we are able to assist clients at every step along the product life cycle. Pepper's Boston office opened in October 2006. Lawyers in the office focus on corporate and securities, corporate restructuring and bankruptcy, tax, complex corporate and commercial litigation, patent litigation and other intellectual property matters.

Santhera Pharmaceuticals USA

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of severe neuromuscular diseases. Santhera’s vision is to become a leading specialty pharmaceutical company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indications with no current therapy.


Alcami specializes in all phases of pharmaceutical development — from critical preformulation studies to commercial product lifecycle management. Over the past 30 years, Alcami has supported more than 500 Investigational New Drug (IND) filings and over 50 New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA) and New Animal Drug Applications (NADA). Our fully integrated laboratory services are well established and ready to help our clients get the most out of their portfolios The advantage of using Alcami is our consistent, flexible, and reliable on-time delivery. The majority of compendial raw materials are released in 10 business days or less with an available option for expedited services as short as one day. We have experience in testing a broad range of compendial monographs and vendor specific needs, tailored to your specific requirement — from partial to full monograph testing. Alcami is also known for its industry leading experience and expertise in formulation development, biotechology, and analytical method development. Alcami holds an exemplary compliance record. When you partner with us, you receive access to our analytical centers of excellence ensuring fast and responsive support, along with the industries best customer service experience.


HealthCore, Inc. is the wholly-owned, independently operating health outcomes research subsidiary of Anthem (NYSE: ANTM), Inc. We work with life sciences companies, payers and providers, and government and academic organizations to provide real-world evidence in support of a wide variety of health care decisions. Our research capabilities include extensive experience in HEOR, Late Phase, Safety and Epidemiology and Survey-Based research services and solutions with our work designed to improve quality, safety and affordability in health care. With more than 20 years of experience, clinical and scientific research expertise, and exclusive access to a robust, integrated research environment containing information on nearly 60 million individuals from multiple health plans across the U.S., HealthCore delivers unparalleled clarity and actionable information to health care decision makers.

Eyegate Pharma

Eyegate Pharmaceuticals, Inc. was established upon the need for a safer, more efficient method to administer ocular therapeutics. At present, physicians are limited to topical instillations, systemic administrations, intravitreal or periocular injections, and intraocular depots, all of which are associated with deleterious side effects. Eyegate has built a technology platform based on the fundamental principles of Iontophoresis. The Eyegate technology was developed at the Bascom Palmer Eye Institute by ophthalmologists specifically for ocular indications. The applicator was designed to avoid contact with the cornea, minimizing the pain and potential cataract formation due to localized heat production. We take advantage of the large surface area of the sclera allowing the current density to be dispersed thus increasing the tolerated dose of applied current. Molecules as large as 150 kD have been shown to passively traverse the sclera with impressive deposition efficiencies. A safe non-invasive alternative would be welcomed by ophthalmologists and patient advocacy groups alike.


Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. We are developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs). Our tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level. Our discoveries and R&D programs have been the subject of more than 30 peer-reviewed publications and have been supported by corporate investment and grants from the NIH, SBIR, U.S. Department of Treasury, and State of Texas. We control a portfolio of 30 issued and 6 pending patents covering tumor suppressors, therapeutics, diagnostics, nanovesicle delivery systems, and manufacturing processes. Oncoprex™, our lead product candidate, regulates the activation of multiple oncogenic kinases and has shown synergistic anti-cancer activity when combined with a number of kinase inhibitor drugs (KIs). Oncoprex is expected to participate in major oncology markets in combination with KIs.


PharmaLegacy Laboratories was founded in 2008 as a preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Inflammation/Auto-Immune Diseases, Liver/Metabolic Diseases, Bone/Orthopaedics, and Oncology. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. Our animal disease models cover a wide range of species from rodents to Non Human Primates (NHP). Our unique NHP disease models form one of the key strengths of our services. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services from early proof of concept of therapeutics to fulfillment of regulatory requirements.

CJ Research Center

CJ Research Center is an exciting new company founded as the hub of CJ's innovative biotechnology. As a subsidiary of the South Korean conglomerate, CJ ChielJedang, the CJ Research Center will benefit from many of the bio businesses CJ CheilJedang has established around the world, including: food, food ingredient, animal feed, and amino acid/nucleotide feed supplements. CJ recognized the potential commercial synergy between these bio businesses and the proprietary PHA biopolymer technology pioneered by Metabolix/Yield 10 Biosciences. Creating a firm foundation for the new Research Center, CJ acquired the core technology of Metabolix/Yield10 as well as the molecular biology and fermentation labs located in Woburn, MA. Taking advantage of the vast academic and industry resources clustered in the Boston/Cambridge area, CJ has assembled a world class technical team to continue development of the biopolymer technology through advanced bacterial strain engineering methods and fermentation process precision and throughput improvements. The CJ Research Center will explore new technologies and pursue unique, cutting-edge approaches to expand into other life sciences.

See all MassBio News